Mitapivat and Sebetralstat: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Mitapivat
Sebetralstat
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Reduced sebetralstat exposure and reduced efficacy of sebetralstat
Interaction Deep Dive
Avoid coadministration of sebetralstat with a strong or moderate CYP3A4 inducer as it may reduce sebetralstat exposure, which may reduce the efficacy of sebetralstat. In drug interaction studies, sebetralstat Cmax decreased by 66% and AUC(0 to inf) decreased by 83% following concomitant administration with phenytoin (a strong CYP3A4 inducer) 100 mg three times daily for 15 days. Sebetralstat Cmax decreased by 63% and AUC(0 to inf) decreased by 79% following concomitant administration with efavirenz (a moderate CYP3A4 inducer) 600 mg once daily for 14 days1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of sebetralstat
Literature reports
2 reports — tap to read
a) In drug interaction studies, sebetralstat Cmax decreased by 66% and AUC(0 to inf) decreased by 83% following concomitant administration with phenytoin (a strong CYP3A4 inducer) 100 mg three times daily for 15 days 1.
b) Sebetralstat Cmax decreased by 63% and AUC(0 to inf) decreased by 79% following concomitant administration with efavirenz (a moderate CYP3A4 inducer) 600 mg once daily for 14 days 1.
Common questions
Can I take Mitapivat and Sebetralstat together?
Reduced sebetralstat exposure and reduced efficacy of sebetralstat Always confirm with your pharmacist or prescriber before making any change.
How serious is the Mitapivat and Sebetralstat interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Mitapivat or Sebetralstat need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: EKTERLY(R) oral tablets, sebetralstat oral tablets. KalVista Pharmaceuticals, Inc (per manufacturer), Cambridge, MA, 2025. DailyMed
Keep reading about Mitapivat
Keep reading about Sebetralstat
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist